Biotechnology Cancer Cures Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Biotechnology Cancer Cures

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mike McFarland who wrote (57)	5/22/1999 2:43:00 AM
From: Mike McFarland	Read Replies (1) of 226

Carboplatin/Paclitaxel Preferable to Cisplatin/Paclitaxel in Optimal Stage III Epithelial Ovarian Cancer oncolink.com Cyclophosphamide/Cisplatin Possibly Preferable to 32P in Treament of Early High-Risk Ovarian Cancer oncolink.com Sequential Couplets of Cisplatin/Topotecan and Cisplatin/Paclitaxel as First-Line Therapy in Advanced Epithelial Ovarian Cancer oncolink.com While I'm here, what again is promising in phase II? I think MOGN's MGI 114 BIOM's Theratope Sugen 101 and Onyx 015 in there too, I cannot remember-- ah, here is something, get this in here before the edit window closes: Ligand--Panretin? Then as far as what is used now, see above, and also the Herceptin, the her2 antibody. Well that is first draft, sombody else help me out here.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next